Fig. 4From: Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life dataMedian headache days and intensity and patients distribution according to MIDAS and HIT-6 scores during the 3 months before onabotulinumtoxin A initiation and during the final 3 months of follow-up. Results are stratified by response status. The asterisk (*) identifies significant changes compared with pre-treatment. NR indicates non-responders; AR, anytime responders; SR, sustained respondersBack to article page